April 19, 2019
Article
What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?
Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.
The high cost of targeted treatments for acute myeloid leukemia has made it difficult for patients to access these therapies.
April 17, 2019
Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses key trials in prostate cancer research.
Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed the recent updates to the American Cancer Society's screening guidelines for colorectal cancer.
April 16, 2019
Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia.
Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments.
Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies.
Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed emerging trends in oncology care.
April 15, 2019
In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia.
